Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen

Inclusion Criteria:

Biologic high risk Multiple Myeloma:

Stage II/III Multiple Myeloma, any of: t(4; 14), t(14; 16),(14:20) by Fish; 17P- by conventional cytogenetics or Fish; ∆13 by conventional cytogenetics; Hypodiploidy by conventional cytogenetics.

Relapsed or persistent multiple myeloma after ASCT.
Persistent multiple myeloma, regardless of previous therapies.
Plasma cell leukemia, regardless of previous therapies.
Age up to 70 years old (less than 71 years old at the date of transplant admission).
Disease status: in CR, nCR, VGPR, PR or stable disease within 1 month of admission
Patients with non-secretory and oligosecretory disease are eligible if they meet certain criteria within 2 weeks prior to the transplant.
Specific renal, liver, cardiac, and pulmonary function requirements(all must be met within 30 days of transplant admission)

Exclusion Criteria:

Persistent invasive infections, not controlled by antimicrobials.
HIV-1/HIV-2 or HTLV-1/HTLV-2 seropositivity.
Uncontrolled medical or psychiatric disorder.
No response or progressive disease at the time of transplantation.
Pregnancy